These findings support further investigation of ABvac40 as a potential disease-modifying therapy. 3 key findings →
Design: clinical trial Participants: 124 Evidence: high
Full summary, score breakdown and related studies → Original source
34,580 published Alzheimer's and dementia studies, each summarized in plain English, scored out of 100 and linked to the original paper.
These findings support further investigation of ABvac40 as a potential disease-modifying therapy. 3 key findings →
Design: clinical trial Participants: 124 Evidence: high
Full summary, score breakdown and related studies → Original source
Slowing of cognitive and functional decline, and amyloid reduction in gantenerumab group compared to placebo group were greater in Japanese-GRADUATE than in the global-GRADUATE and JP40959. 5 key findings →
Design: clinical trial Participants: 1,965 Evidence: high
Full summary, score breakdown and related studies → Original source
Donanemab treatment resulted in earlier and greater AP clearance compared to aducanumab. 5 key findings →
Design: clinical trial Participants: 148 Evidence: high
Full summary, score breakdown and related studies → Original source
ABvac40 showed favorable long-term safety and durable immunogenicity, supporting further clinical development. 2 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
The safety profile of aducanumab remained unchanged in the LTE of PRIME. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Temporal imaging variables may provide independent prognostic information beyond baseline risk, supporting a dynamic model of hemorrhagic risk in Alzheimer's disease. 2 key findings →
Design: longitudinal study Participants: 1,069 Evidence: moderate
Full summary, score breakdown and related studies → Original source
MCH-Guard offers a flexible clinical decision-support tool for optimizing spontaneous MCH and ARIA-H surveillance. 1 key finding →
Design: longitudinal study Participants: 813 Evidence: moderate
Full summary, score breakdown and related studies → Original source
VE seems to be rare at baseline in patients with AD in clinical trials, 2 of 2,762 associated with AD. 5 key findings →
Design: clinical trial Participants: 621 Evidence: high
Full summary, score breakdown and related studies → Original source
A 45% reduction of rate of hippocampal atrophy was observed in prodromal AD following 1 year of treatment with donepezil compared with placebo. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Antibody administration was well tolerated with doses up to 400 mg weekly. 2 key findings →
Design: clinical trial Participants: 52 Evidence: high
Full summary, score breakdown and related studies → Original source
This review identified previously published MCIDs for AD trial endpoints. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
ARIA are not associated with long-term parenchymal reduction; rather, they are linked to a fluid shift from the external space to the ventricles. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These findings support the short-term efficacy and safety of Lecanemab in early AD and highlight plasma biomarkers as a treatment-responsive biomarker. 3 key findings →
Design: cohort study Participants: 68 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Numerous clinical trials of anti-amyloid beta (Aβ) immunotherapy in Alzheimer's disease have been performed. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years. 5 key findings →
Participants: 54 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Pooled MMRM analyses showed a statistically significant effect of solanezumab across cognitive and functional outcome measures. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
7T MRI provides superior ARIA-H detection and iron dynamics monitoring, supporting its role in risk stratification and therapy assessment for lecanemab-treated patients. 3 key findings →
Design: longitudinal study Participants: 72 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Increasing age and hypertension are significant risk factors of CMHs. 4 key findings →
Design: cross-sectional Participants: 1,414 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The non-linear function indicates that a higher dose is not necessarily better in multidomain interventions. 3 key findings →
Design: randomized controlled trial Participants: 749 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These findings describe solanezumab effects on efficacy/safety measures in a mild AD population. 3 key findings →
Design: clinical trial Participants: 659 Evidence: low
Full summary, score breakdown and related studies → Original source
Lecanemab exhibited favorable 12-month safety, with no clear evidence of cognitive decline, and BBMs hold potential for treatment guidance. 2 key findings →
Participants: 1,042 Evidence: moderate
Full summary, score breakdown and related studies → Original source
ARIA-E incidence was 2.0% in non-carriers and 6.2% in εε4/εε4 homozygotes (εε4/εε4-versus-non-carrier OR 3.25, versus 8.49 in Clarity AD and 8.32 in Japan post-marketing surveillance). 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Enrollment began in March 2001 and ended in December 2004 when treatments were suspended because of concerns regarding cardiovascular safety of the treatments. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Although early assessment has significant up-front costs, identifying AD patients at an early stage results in cost savings and health benefits compared with no treatment or treatment in the absence of early assessment. 4 key findings →
Design: longitudinal study Participants: 17 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 34,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 34,580 records, built mostly from automated pulls of Europe PMC (68.8% of the library) and OpenAlex (14.7%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,050 records (3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated